Free Trial

Cartesian Therapeutics (RNAC) Competitors

Cartesian Therapeutics logo
$11.37 +0.48 (+4.41%)
Closing price 04:00 PM Eastern
Extended Trading
$11.52 +0.16 (+1.36%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RNAC vs. AMPH, DYN, ABCL, PAHC, WVE, ELVN, VERV, NTLA, COLL, and AKBA

Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), WAVE Life Sciences (WVE), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry.

Cartesian Therapeutics vs. Its Competitors

Cartesian Therapeutics (NASDAQ:RNAC) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by insiders. Comparatively, 27.5% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cartesian Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500.

In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Amphastar Pharmaceuticals and 0 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.87 beat Amphastar Pharmaceuticals' score of 0.44 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cartesian Therapeutics Very Positive
Amphastar Pharmaceuticals Neutral

Cartesian Therapeutics presently has a consensus price target of $41.25, suggesting a potential upside of 262.80%. Amphastar Pharmaceuticals has a consensus price target of $32.33, suggesting a potential upside of 37.12%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cartesian Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Amphastar Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

Amphastar Pharmaceuticals has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cartesian Therapeutics$38.91M7.58-$77.42M-$52.83-0.22
Amphastar Pharmaceuticals$731.97M1.52$159.52M$2.768.54

Amphastar Pharmaceuticals has a net margin of 19.38% compared to Cartesian Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 22.20% beat Cartesian Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cartesian TherapeuticsN/A N/A -7.01%
Amphastar Pharmaceuticals 19.38%22.20%10.40%

Summary

Amphastar Pharmaceuticals beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Cartesian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNAC vs. The Competition

MetricCartesian TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$282.64M$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E Ratio-0.2221.3126.1719.90
Price / Sales7.58278.47414.67113.66
Price / CashN/A41.4736.1356.90
Price / Book-42.117.518.055.38
Net Income-$77.42M-$55.05M$3.15B$248.50M
7 Day Performance5.67%2.45%1.85%2.97%
1 Month Performance13.93%7.33%4.81%6.02%
1 Year Performance-27.90%5.38%34.86%20.39%

Cartesian Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNAC
Cartesian Therapeutics
1.9779 of 5 stars
$11.37
+4.4%
$41.25
+262.8%
-55.1%$282.64M$38.91M-0.2264Positive News
AMPH
Amphastar Pharmaceuticals
4.2872 of 5 stars
$22.96
-0.5%
$32.33
+40.8%
-39.4%$1.09B$731.97M8.322,028
DYN
Dyne Therapeutics
3.4938 of 5 stars
$9.52
-0.5%
$41.13
+332.0%
-75.5%$1.09BN/A-2.65100
ABCL
AbCellera Biologics
2.2401 of 5 stars
$3.43
-5.0%
$8.33
+143.0%
+25.5%$1.08B$28.83M-6.12500High Trading Volume
PAHC
Phibro Animal Health
3.5669 of 5 stars
$25.54
-0.5%
$21.80
-14.6%
+56.2%$1.04B$1.02B32.741,940
WVE
WAVE Life Sciences
4.5404 of 5 stars
$6.50
-2.5%
$20.50
+215.4%
+24.4%$1.04B$108.30M-7.74240Positive News
ELVN
Enliven Therapeutics
2.4691 of 5 stars
$20.06
-3.0%
$39.60
+97.4%
-13.4%$1.01BN/A-10.4550Analyst Forecast
VERV
Verve Therapeutics
3.5023 of 5 stars
$11.23
-0.6%
$14.57
+29.8%
+126.5%$1.01B$32.33M-5.32110
NTLA
Intellia Therapeutics
4.6699 of 5 stars
$9.38
-1.9%
$33.37
+255.7%
-56.0%$990.25M$57.88M-1.79600
COLL
Collegium Pharmaceutical
4.0327 of 5 stars
$29.57
-1.2%
$43.75
+48.0%
-7.1%$961.71M$664.28M24.24210News Coverage
AKBA
Akebia Therapeutics
4.3431 of 5 stars
$3.64
-0.3%
$6.75
+85.4%
+259.0%$958.62M$160.18M-17.33430News Coverage
Positive News
Insider Trade

Related Companies and Tools


This page (NASDAQ:RNAC) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners